The "priority pathogens" include germs that cause deadly infections of the bloodstream, lungs, brain or urinary tract, but do not respond to an ever-longer list of medicines.
In more and more cases, none of the existing drugs work.
"Antibiotic resistance is growing, and we are fast running out of treatment options," said Marie-Paule Kieny, assistant director-general at the World Health Organization (WHO), which published the list.
"If we leave it to market forces alone, the new antibiotics we most urgently need are not going to be developed in time."
The agency previously warned that if nothing is done the world was headed for a "post-antibiotic" era in which common infections and minor injuries become killers once again.
Bacteria can develop drug resistance when people take incorrect doses of antibiotics. Resistant strains can be contracted directly from animals, water and air, or other people.
When the most common antibiotics fail to work, more expensive types must be tried, resulting in longer illness and treatment, often in hospital.
The list is divided into three categories of priority: critical, high and medium.
The top priorities are superbugs resistant to carbapenem antibiotics -- a last-resort treatment for life-threatening infections often spread in hospitals, nursing homes and among patients who rely on ventilators and catheters.
In January, an American woman died of an infection -- resistant to all 27 available antibiotics -- caused by a germ called Enterobacteriaceae which is on the WHO's critical list.
The list will be discussed with health experts of the G20 group of major economies in Berlin this week, it added.
"New antibiotics targeting this priority list of pathogens will help to reduce deaths due to resistant infections around the world," said Evelina Tacconelli of the University of Tuebingen in Germany, who helped draw up the index.
Tuberculosis was not listed because well-funded programmes already exist to develop new antibiotics, said the WHO.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app